N/A
93.317
The purpose of the Emerging Infections Programs (EIP) is to assist in local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. The EIP cooperative agreement was formed in 1995 as a key component of CDC’s national strategy to address and reduce emerging infectious disease (EID) threats. The EIP is a population-based network of state health agencies and their collaborators, including (but not limited to) academic institutions, local health departments, public health and clinical laboratories, infection control professionals, and healthcare providers. The network plays a critical role in conducting surveillance and applied epidemiologic and laboratory research, implementing and evaluating prevention and intervention projects, and responding quickly to new infectious disease issues. The unique strength of the EIP lies in the network’s ability to quickly translate surveillance and research activities into informed policy and public health practice.
This chart shows obligations for the program by fiscal year. All data for this chart was provided by the
administering agency and sourced from SAM.gov, USASpending.gov, and Treasury.gov.
For more information on each of these data sources, please see the
About the data page.
Continuation funding was provided for 10 EIP grantees in FY 2016 Only one grantee was awarded funds under this CFDA in FY 2016.
10 applications were received and funded.
Single Audit Applies (2 CFR Part 200 Subpart F):
For additional information on single audit requirements for this program, review the current Compliance Supplement.
OMB is working with the U.S. Government Accountability Office (GAO) and agency offices of inspectors general to include links to relevant oversight reports. This section will be updated once this information is made available.